ondon, Ontario, June 10th, 2024: London Research & Pharmaceuticals presented notable pre-clinical data about its lead compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) conference in Madrid, Spain, May 5th to May 8th, 2024.
LRP-661’s data highlights its superior safety, efficacy, bioavailability, and PK in multiple species. Furthermore, LRP-661’s oral formulation ability compared to cannabidiol, marks a significant advancement in the field of epilepsy treatment. Notably, the compound demonstrates exceptional efficacy in PTZ fully kindled mice, Maximal Electroshock Seizure (MES), MES Threshold, and pentylenetetrazol (PTZ)–induced seizure data.